BidaskClub lowered shares of EXACT Sciences (NASDAQ:EXAS) from a buy rating to a hold rating in a research report report published on Tuesday.

Several other equities research analysts have also commented on EXAS. Benchmark restated a buy rating and set a $60.00 target price (up previously from $50.00) on shares of EXACT Sciences in a research report on Tuesday, October 31st. Leerink Swann restated an outperform rating and set a $50.00 target price (up previously from $45.00) on shares of EXACT Sciences in a research report on Thursday, September 21st. Bank of America increased their price target on EXACT Sciences from $56.00 to $58.00 and gave the stock a buy rating in a report on Tuesday, October 31st. Zacks Investment Research upgraded EXACT Sciences from a hold rating to a buy rating and set a $51.00 price target on the stock in a report on Tuesday, September 26th. Finally, Robert W. Baird increased their price target on EXACT Sciences from $49.00 to $56.00 and gave the stock an outperform rating in a report on Tuesday, October 31st. Nine research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. EXACT Sciences currently has a consensus rating of Hold and an average target price of $50.58.

Shares of EXACT Sciences (EXAS) opened at $50.22 on Tuesday. EXACT Sciences has a 52-week low of $13.05 and a 52-week high of $63.60. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01.

EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.07. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The company had revenue of $72.60 million for the quarter, compared to analyst estimates of $65.03 million. During the same quarter in the prior year, the company earned ($0.36) EPS. The firm’s revenue for the quarter was up 158.4% compared to the same quarter last year. analysts predict that EXACT Sciences will post -1.12 earnings per share for the current year.

In other EXACT Sciences news, insider Graham Peter Lidgard sold 81,025 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $3,821,139.00. Following the transaction, the insider now owns 366,519 shares in the company, valued at $17,285,036.04. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP D Scott Coward sold 29,115 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $1,373,063.40. Following the completion of the sale, the senior vice president now directly owns 64,991 shares of the company’s stock, valued at $3,064,975.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 595,396 shares of company stock worth $32,953,769. Corporate insiders own 4.00% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio raised its stake in shares of EXACT Sciences by 69.7% in the third quarter. Public Employees Retirement System of Ohio now owns 122,201 shares of the medical research company’s stock worth $5,758,000 after purchasing an additional 50,185 shares during the last quarter. Piedmont Investment Advisors LLC purchased a new stake in shares of EXACT Sciences in the third quarter worth approximately $514,000. California Public Employees Retirement System raised its stake in shares of EXACT Sciences by 2.8% in the third quarter. California Public Employees Retirement System now owns 190,338 shares of the medical research company’s stock worth $8,969,000 after purchasing an additional 5,238 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of EXACT Sciences by 117.9% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,730 shares of the medical research company’s stock worth $327,000 after purchasing an additional 3,642 shares during the last quarter. Finally, AlphaStar Capital Management LLC purchased a new stake in shares of EXACT Sciences in the third quarter worth approximately $322,000. 82.39% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/exact-sciences-exas-lowered-to-hold-at-bidaskclub/1760919.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.